| Year |
Citation |
Score |
| 2021 |
Redman-Rivera LN, Shaver TM, Jin H, Marshall CB, Schafer JM, Sheng Q, Hongo RA, Beckermann KE, Wheeler FC, Lehmann BD, Pietenpol JA. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nature Communications. 12: 5184. PMID 34465782 DOI: 10.1038/s41467-021-25359-z |
0.393 |
|
| 2021 |
Marshall CB, Beeler JS, Lehmann BD, Gonzalez-Ericsson P, Sanchez V, Sanders ME, Boyd KL, Pietenpol JA. Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell Death & Disease. 12: 745. PMID 34315849 DOI: 10.1038/s41419-021-04017-8 |
0.316 |
|
| 2020 |
Schafer JM, Pietenpol JA. Tyramide Signal-Amplified Immunofluorescence of MYCN and MYC in Human Tissue Specimens and Cell Line Cultures. Bio-Protocol. 10: e3677. PMID 33659347 DOI: 10.21769/BioProtoc.3677 |
0.308 |
|
| 2020 |
Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, ... ... Pietenpol JA, et al. Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science Translational Medicine. 12. PMID 32161105 DOI: 10.1126/Scitranslmed.Aaw8275 |
0.363 |
|
| 2020 |
Lander EM, Lehmann BD, Shah PD, Dees EC, Ballinger TJ, Pohlmann PR, Santa-Maria CA, Shyr Y, Mayer IA, Park BH, Pietenpol JA, Abramson VG. A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. 38: TPS1112-TPS1112. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps1112 |
0.311 |
|
| 2019 |
Beeler JS, Marshall CB, Gonzalez-Ericsson PI, Shaver TM, Santos Guasch GL, Lea ST, Johnson KN, Jin H, Venters BJ, Sanders ME, Pietenpol JA. p73 regulates epidermal wound healing and induced keratinocyte programming. Plos One. 14: e0218458. PMID 31216312 DOI: 10.1371/Journal.Pone.0218458 |
0.501 |
|
| 2019 |
Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sanchez V, Shyr Y, Sanders ME, Pietenpol JA. Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations. Molecular Cancer Research : McR. PMID 31186280 DOI: 10.1158/1541-7786.Mcr-19-0257 |
0.361 |
|
| 2019 |
Gonzalez-Ericsson P, Lehmann B, Mobley B, Chen Y, Pietenpol J, Sanders M. Abstract P2-06-09: Identification of oncogenic gene fusions in triple-negative breast cancer metastatic to the brain Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-06-09 |
0.441 |
|
| 2019 |
Lehmann BD, Colaprico A, Chen J, Wang L, Pietenpol J, Chen X. Abstract LB-301: Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-301 |
0.384 |
|
| 2018 |
Richmond BW, Du RH, Marshall C, Pietenpol J, Polosukhin VV, Blackwell TS. p73 Is Required for pIgR Expression in the Respiratory Epithelium. Annals of the American Thoracic Society. 15: S290. PMID 30759000 DOI: 10.1513/Annalsats.201806-410Mg |
0.3 |
|
| 2018 |
Fuertes-Alvarez S, Maeso-Alonso L, Villoch-Fernandez J, Wildung M, Martin-Lopez M, Marshall C, Villena-Cortes AJ, Diez-Prieto I, Pietenpol JA, Tissir F, Lizé M, Marques MM, Marin MC. p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton. Cell Death & Disease. 9: 1183. PMID 30518789 DOI: 10.1038/S41419-018-1205-6 |
0.386 |
|
| 2018 |
Santos Guasch GL, Beeler JS, Marshall CB, Shaver TM, Sheng Q, Johnson KN, Boyd KL, Venters BJ, Cook RS, Pietenpol JA. p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. Iscience. 8: 236-249. PMID 30340069 DOI: 10.1016/J.Isci.2018.09.018 |
0.529 |
|
| 2018 |
Schafer J, Lehmann B, Redman L, Liu P, Stubbs M, Ruggeri B, Scherle P, Pietenpol J. Abstract P2-09-24: Combination treatment with bromodomain and extra-terminal motif inhibitors in triple-negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-09-24 |
0.375 |
|
| 2017 |
Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. Bmc Cancer. 17: 241. PMID 28376728 DOI: 10.1186/S12885-017-3237-1 |
0.362 |
|
| 2017 |
Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders M, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KN, Sanchez V, Rosenbluth JM, Dillon PM, Forrero-Torres A, ... ... Pietenpol JA, et al. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28270498 DOI: 10.1158/1078-0432.Ccr-16-3055 |
0.716 |
|
| 2017 |
Liu PCC, Lehmann BD, Ruggeri B, DiMatteo D, Schafer JM, Lu J, Lee SH, Lin L, Burn TC, Diamond M, Volgina A, Wu L, Hollis G, Huber R, Pietenpol JA, et al. Abstract 531: Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in genetically-defined models of triple-negative breast cancer Cancer Research. 77: 531-531. DOI: 10.1158/1538-7445.Am2017-531 |
0.384 |
|
| 2017 |
Schafer J, Lehmann B, Liu P, Stubbs M, Scherle P, Pietenpol J. Abstract 1518: Mechanisms of bromodomain and extra-terminal motif inhibitor (BETi) sensitivity in triple-negative breast cancer (TNBC) Cancer Research. 77: 1518-1518. DOI: 10.1158/1538-7445.Am2017-1518 |
0.354 |
|
| 2016 |
Cowen SD, Russell D, Dakin LA, Chen H, Larsen NA, Godin R, Throner S, Zheng X, Molina A, Wu J, Cheung T, Howard T, Garcia-Arenas R, Keen N, Pendleton CS, ... Pietenpol JA, et al. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors. Journal of Medicinal Chemistry. 59: 11079-11097. PMID 28002961 DOI: 10.1021/Acs.Jmedchem.6B01303 |
0.343 |
|
| 2016 |
Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, Brenin DR, Pietenpol JA, O'Doherty GA, Lannigan DA. Development of a RSK Inhibitor as a Novel Therapy for Triple Negative Breast Cancer. Molecular Cancer Therapeutics. PMID 27528706 DOI: 10.1158/1535-7163.Mct-16-0106 |
0.325 |
|
| 2016 |
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. Plos One. 11: e0157368. PMID 27310713 DOI: 10.1371/Journal.Pone.0157368 |
0.336 |
|
| 2016 |
Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer Research. PMID 27231203 DOI: 10.1158/0008-5472.Can-16-0058 |
0.378 |
|
| 2016 |
Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, Shyr Y, Venters BJ, Magnuson MA, Pietenpol JA. p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Cell Reports. PMID 26947080 DOI: 10.1016/J.Celrep.2016.02.035 |
0.817 |
|
| 2016 |
Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. Bmc Cancer. 16: 143. PMID 26908167 DOI: 10.1186/S12885-016-2198-0 |
0.304 |
|
| 2015 |
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. PMID 25972361 DOI: 10.18632/Oncotarget.3860 |
0.386 |
|
| 2015 |
Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Plos One. 10: e0125482. PMID 25965342 DOI: 10.1371/Journal.Pone.0125482 |
0.338 |
|
| 2015 |
Wilson AJ, Lehmann BD, Liu Q, Uddin J, Elleman A, Crews B, Saskowski J, Pietenpol J, Marnett LJ, Khabele D. Abstract POSTER-BIOL-1350: Dissecting cellular and molecular consequences of disrupting cyclooxygenase-1 activity in ovarian cancer Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1350 |
0.407 |
|
| 2015 |
Seitz RS, Hout DR, Morris SW, Smith RB, Lehmann BD, Chen X, Pietenpol JA, Ring BZ. Abstract P6-08-04: Creation of a robust algorithm utilizing minimal gene sets normalized against a reference gene set to identify triple-negative breast cancer (TNBC) subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-08-04 |
0.378 |
|
| 2015 |
Jovanovic B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL. Abstract P6-03-04: TGF-β receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-03-04 |
0.412 |
|
| 2015 |
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gomez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. Abstract P3-04-03: PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-04-03 |
0.344 |
|
| 2015 |
Wilson AJ, Lehmann BD, Saskowski J, Uddin J, Daniel C, Crews BC, Liu Q, Zhao S, Son D, Pietenpol JA, Marnett LJ, Khabele D. Abstract 2068: Cyclooxygenase-1 gene expression contributes to multiple oncogenic pathways in high grade serous ovarian cancer Cancer Research. 75: 2068-2068. DOI: 10.1158/1538-7445.Am2015-2068 |
0.401 |
|
| 2014 |
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research : Bcr. 16: 406. PMID 25103565 DOI: 10.1186/S13058-014-0406-X |
0.328 |
|
| 2014 |
Jovanovi? B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Breast Cancer Research : Bcr. 16: R69. PMID 24985072 DOI: 10.1186/Bcr3684 |
0.407 |
|
| 2014 |
Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Research. 74: 3180-94. PMID 24662921 DOI: 10.1158/0008-5472.Can-13-3415 |
0.429 |
|
| 2014 |
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, ... ... Pietenpol JA, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discovery. 4: 232-45. PMID 24356096 DOI: 10.1158/2159-8290.Cd-13-0286 |
0.356 |
|
| 2014 |
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. The Journal of Pathology. 232: 142-50. PMID 24114677 DOI: 10.1002/Path.4280 |
0.317 |
|
| 2014 |
Abramson VG, Lehmann B, Mayer IA, Arteaga CL, Pietenpol JA. TBCRC028: A phase Ib/II trial of GDC-0941 (a PI3K inhibitor) in combination with cisplatin in metastatic androgen receptor-negative triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps1148 |
0.347 |
|
| 2014 |
Wilson AJ, Lehmann BD, Ussin J, Elleman A, Crews B, Saskowski J, Pietenpol J, Marnett LJ, Khabele D. Abstract 4928: Cyclooxygenase-1 as a target for molecular imaging of high grade serous ovarian cancer Cancer Research. 74: 4928-4928. DOI: 10.1158/1538-7445.Am2014-4928 |
0.372 |
|
| 2013 |
Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2723-33. PMID 23549873 DOI: 10.1158/1078-0432.Ccr-12-2986 |
0.306 |
|
| 2013 |
Landis MD, Lehmann BD, Pietenpol JA, Chang JC. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Research : Bcr. 15: 201. PMID 23339383 DOI: 10.1186/Bcr3355 |
0.311 |
|
| 2013 |
Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. Journal of Clinical Oncology. 31: 1005-1005. DOI: 10.1200/Jco.2013.31.15_Suppl.1005 |
0.338 |
|
| 2013 |
Jovanovic B, Chen SX, Lehmann BD, Johnson KN, Sanchez V, Kuba MG, Sanders ME, Mayer IA, Moses HL, Pietenpol JA. Abstract 4698: Gene expression profiles of triple negative breast cancer epithelial and stromal cells are predictive of treatment response. Cancer Research. 73: 4698-4698. DOI: 10.1158/1538-7445.Am2013-4698 |
0.342 |
|
| 2013 |
Mayer I, Jovanovic B, Abramson V, Mayer E, Sanders M, Bardia A, Dillon P, Kuba M, Carpenter J, Chang J, Lehmann B, Meszoely I, Grau A, Shyr Y, Arteaga C, ... ... Pietenpol J, et al. Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd1-6 |
0.367 |
|
| 2012 |
Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3648-50. PMID 22965952 DOI: 10.1200/Jco.2012.44.0412 |
0.557 |
|
| 2012 |
Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Informatics. 11: 147-56. PMID 22872785 DOI: 10.4137/Cin.S9983 |
0.312 |
|
| 2012 |
Lehmann B, Bauer J, Schafer J, Tang L, Pendleton C, Sanders M, Pietenpol J. Abstract P6-05-03: Targeted inhibition of recurrent PIK3CA mutations synergizes with bicalutamide in AR-expressing triple negative breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-05-03 |
0.412 |
|
| 2012 |
Jovanovic B, Ashby W, Zijlstra A, Pietenpol J, Moses H. Abstract P3-05-09: The role of TGF-beta receptor type 3 in breast cancer progression Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-05-09 |
0.381 |
|
| 2012 |
Pietenpol J. Abstract ES2-2: Triple Negative Breast Cancer: Subtypes, Molecular Targets, and Therapeutic Approaches Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Es2-2 |
0.371 |
|
| 2011 |
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation. 121: 2750-67. PMID 21633166 DOI: 10.1172/Jci45014 |
0.384 |
|
| 2011 |
Rosenbluth JM, Mays DJ, Jiang A, Shyr Y, Pietenpol JA. Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 108: 2076-81. PMID 21245298 DOI: 10.1073/Pnas.1011936108 |
0.816 |
|
| 2011 |
Bauer JA, Lehmann BD, Glick G, Cortez D, Lee E, Pietenpol JA. Abstract 951: Loss-of-function screening identifies therapeutic targets for triple negative breast cancer (TNBC) Cancer Research. 71: 951-951. DOI: 10.1158/1538-7445.Am2011-951 |
0.443 |
|
| 2011 |
Lehmann BD, Bauer JA, Sanders ME, Chakravarthy BA, Pietenpol JA. Abstract 4411: γH2AX as a marker of genomic instability predicts cisplatin sensitivity in triple negative breast cancer cells Cancer Research. 71: 4411-4411. DOI: 10.1158/1538-7445.Am2011-4411 |
0.379 |
|
| 2011 |
Mayer I, Means-Powell J, Abramson V, Shyr Y, Balko J, Kuba M, Gharavi H, Schlabach L, Arteaga C, Pietenpol J. PD09-06: Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer (MBC). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd09-06 |
0.451 |
|
| 2010 |
Barton CE, Johnson KN, Mays DM, Boehnke K, Shyr Y, Boukamp P, Pietenpol JA. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. Cell Death & Disease. 1: e74. PMID 21151771 DOI: 10.1038/Cddis.2010.49 |
0.75 |
|
| 2010 |
Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Research and Treatment. 124: 723-32. PMID 20878462 DOI: 10.1007/S10549-010-1181-8 |
0.304 |
|
| 2010 |
Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Research : Bcr. 12: R41. PMID 20576088 DOI: 10.1186/Bcr2595 |
0.375 |
|
| 2010 |
Eby KG, Rosenbluth JM, Mays DJ, Marshall CB, Barton CE, Sinha S, Johnson KN, Tang L, Pietenpol JA. ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy. Molecular Cancer. 9: 95. PMID 20429933 DOI: 10.1186/1476-4598-9-95 |
0.781 |
|
| 2010 |
Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, ... ... Pietenpol JA, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 681-90. PMID 20068102 DOI: 10.1158/1078-0432.Ccr-09-1091 |
0.738 |
|
| 2010 |
Mayer IA, Meszoely IM, Sanders M, Shyr Y, Abramson VG, Means-Powell JA, Chakravarthy AB, Arteaga CL, Pietenpol JA. A phase II neoadjuvant study of cisplatin/paclitaxel with or without RAD001 in patients with triple-negative (TN) locally advanced breast cancer (BC). Journal of Clinical Oncology. 28: TPS119-TPS119. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps119 |
0.44 |
|
| 2010 |
Adams S, Lymberis SC, Chakravarthy AB, Spicer DV, Hochman T, Donach M, Goldberg JD, Schneider R, Pietenpol JA, Formenti S. Predictors of pathologic response and correlation with long-term outcomes in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced breast cancer (LABC). Journal of Clinical Oncology. 28: 589-589. DOI: 10.1200/Jco.2010.28.15_Suppl.589 |
0.347 |
|
| 2010 |
Formenti S, Adams S, Chakravarthy AB, Lymberis SC, Spicer DV, Bauer JA, Volm M, Roses D, Goldberg JD, Pietenpol JA. Five-year results of preoperative concurrent paclitaxel with radiation in locally advanced breast cancer (LABC). Journal of Clinical Oncology. 28: 567-567. DOI: 10.1200/Jco.2010.28.15_Suppl.567 |
0.341 |
|
| 2009 |
Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA. Evaluation of p63 and p73 antibodies for cross-reactivity. Cell Cycle (Georgetown, Tex.). 8: 3702-6. PMID 19855172 DOI: 10.4161/Cc.8.22.10036 |
0.795 |
|
| 2009 |
Barton CE, Tahinci E, Barbieri CE, Johnson KN, Hanson AJ, Jernigan KK, Chen TW, Lee E, Pietenpol JA. DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. Developmental Biology. 329: 130-9. PMID 19272371 DOI: 10.1016/J.Ydbio.2009.02.036 |
0.796 |
|
| 2009 |
Rosenbluth JM, Pietenpol JA. mTOR regulates autophagy-associated genes downstream of p73. Autophagy. 5: 114-6. PMID 19001857 DOI: 10.4161/Auto.5.1.7294 |
0.824 |
|
| 2008 |
Rosenbluth JM, Pietenpol JA. The jury is in: p73 is a tumor suppressor after all. Genes & Development. 22: 2591-5. PMID 18832062 DOI: 10.1101/Gad.1727408 |
0.794 |
|
| 2008 |
Brown KA, Ham AJ, Clark CN, Meller N, Law BK, Chytil A, Cheng N, Pietenpol JA, Moses HL. Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1. Journal of Cellular Biochemistry. 105: 596-611. PMID 18729074 DOI: 10.1002/Jcb.21860 |
0.319 |
|
| 2008 |
Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. A gene signature-based approach identifies mTOR as a regulator of p73. Molecular and Cellular Biology. 28: 5951-64. PMID 18678646 DOI: 10.1128/Mcb.00305-08 |
0.811 |
|
| 2007 |
Perez CA, Ott J, Mays DJ, Pietenpol JA. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene. 26: 7363-70. PMID 17563751 DOI: 10.1038/Sj.Onc.1210561 |
0.68 |
|
| 2007 |
Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biology & Therapy. 6: 561-70. PMID 17495520 DOI: 10.4161/Cbt.6.4.3851 |
0.33 |
|
| 2007 |
Schavolt KL, Pietenpol JA. p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis. Oncogene. 26: 6125-32. PMID 17404570 DOI: 10.1038/Sj.Onc.1210441 |
0.824 |
|
| 2007 |
Perez CA, Pietenpol JA. Transcriptional programs regulated by p63 in normal epithelium and tumors. Cell Cycle (Georgetown, Tex.). 6: 246-54. PMID 17297308 DOI: 10.4161/Cc.6.3.3801 |
0.732 |
|
| 2006 |
Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Research. 66: 7589-97. PMID 16885358 DOI: 10.1158/0008-5472.Can-06-2020 |
0.732 |
|
| 2006 |
Hinow P, Rogers CE, Barbieri CE, Pietenpol JA, Kenworthy AK, DiBenedetto E. The DNA binding activity of p53 displays reaction-diffusion kinetics. Biophysical Journal. 91: 330-42. PMID 16603489 DOI: 10.1529/Biophysj.105.078303 |
0.637 |
|
| 2006 |
Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1570-6. PMID 16533783 DOI: 10.1158/1078-0432.Ccr-05-2304 |
0.348 |
|
| 2006 |
Barbieri CE, Pietenpol JA. p63 and epithelial biology. Experimental Cell Research. 312: 695-706. PMID 16406339 DOI: 10.1016/J.Yexcr.2005.11.028 |
0.72 |
|
| 2005 |
Hearnes JM, Mays DJ, Schavolt KL, Tang L, Jiang X, Pietenpol JA. Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Molecular and Cellular Biology. 25: 10148-58. PMID 16260627 DOI: 10.1128/Mcb.25.22.10148-10158.2005 |
0.757 |
|
| 2005 |
Barbieri CE, Pietenpol JA. p53 family members: similar biochemistry, different biology. Cancer Biology & Therapy. 4: 419-20. PMID 15908776 DOI: 10.4161/Cbt.4.4.1760 |
0.695 |
|
| 2005 |
Westfall MD, Joyner AS, Barbieri CE, Livingstone M, Pietenpol JA. Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle (Georgetown, Tex.). 4: 710-6. PMID 15846104 DOI: 10.4161/Cc.4.5.1685 |
0.838 |
|
| 2005 |
Maas K, Westfall M, Pietenpol J, Olsen NJ, Aune T. Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Arthritis and Rheumatism. 52: 1047-57. PMID 15818671 DOI: 10.1002/Art.20931 |
0.775 |
|
| 2005 |
Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA. IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Research. 65: 2314-20. PMID 15781645 DOI: 10.1158/0008-5472.Can-04-3449 |
0.765 |
|
| 2004 |
Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. The Laryngoscope. 114: 2063-72. PMID 15564824 DOI: 10.1097/01.Mlg.0000149437.35855.4B |
0.803 |
|
| 2004 |
Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Research : Bcr. 6: R215-31. PMID 15084245 DOI: 10.1186/Bcr778 |
0.31 |
|
| 2004 |
Westfall MD, Pietenpol JA. p63: Molecular complexity in development and cancer. Carcinogenesis. 25: 857-64. PMID 15033906 DOI: 10.1093/Carcin/Bgh148 |
0.831 |
|
| 2003 |
Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Research. 63: 7113-21. PMID 14612504 |
0.765 |
|
| 2003 |
Barbieri CE, Barton CE, Pietenpol JA. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. The Journal of Biological Chemistry. 278: 51408-14. PMID 14555649 DOI: 10.1074/Jbc.M309943200 |
0.717 |
|
| 2003 |
Jo D, Lin Q, Nashabi A, Mays DJ, Unutmaz D, Pietenpol JA, Ruley HE. Cell cycle-dependent transduction of cell-permeant Cre recombinase proteins. Journal of Cellular Biochemistry. 89: 674-87. PMID 12858334 DOI: 10.1002/Jcb.10542 |
0.364 |
|
| 2003 |
Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. The Laryngoscope. 113: 936-9. PMID 12782800 DOI: 10.1097/00005537-200306000-00004 |
0.699 |
|
| 2003 |
Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Molecular and Cellular Biology. 23: 2264-76. PMID 12640112 DOI: 10.1128/Mcb.23.7.2264-2276.2003 |
0.804 |
|
| 2003 |
Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends in Pharmacological Sciences. 24: 139-45. PMID 12628359 DOI: 10.1016/S0165-6147(03)00026-9 |
0.806 |
|
| 2003 |
Anwar A, Dehn D, Siegel D, Kepa JK, Tang LJ, Pietenpol JA, Ross D. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. The Journal of Biological Chemistry. 278: 10368-73. PMID 12529318 DOI: 10.1074/Jbc.M211981200 |
0.538 |
|
| 2002 |
Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology. 181: 475-81. PMID 12505356 DOI: 10.1016/S0300-483X(02)00460-2 |
0.736 |
|
| 2002 |
Pawlak MR, Banik-Maiti S, Pietenpol JA, Ruley HE. Protein arginine methyltransferase I: substrate specificity and role in hnRNP assembly. Journal of Cellular Biochemistry. 87: 394-407. PMID 12397599 DOI: 10.1002/Jcb.10307 |
0.357 |
|
| 2002 |
Sniezek JC, Matheny KE, Burkey BB, Netterville JL, Pietenpol JA. Expression of p63 and 14-3-3sigma in normal and hyperdifferentiated mucosa of the upper aerodigestive tract. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 126: 598-601. PMID 12087324 DOI: 10.1067/Mhn.2002.125302 |
0.482 |
|
| 2002 |
Eichten A, Westfall M, Pietenpol JA, Münger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology. 295: 74-85. PMID 12033767 DOI: 10.1006/Viro.2002.1375 |
0.816 |
|
| 2002 |
Chakravarthy A, Nicholson B, Kelley M, Beauchamp D, Johnson D, Frexes-Steed M, Simpson J, Shyr Y, Pietenpol J. A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. Clinical Breast Cancer. 1: 68-71. PMID 11899393 DOI: 10.3816/Cbc.2000.N.007 |
0.3 |
|
| 2002 |
Coleman SC, Stewart ZA, Day TA, Netterville JL, Burkey BB, Pietenpol JA. Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. Archives of Otolaryngology--Head & Neck Surgery. 128: 167-76. PMID 11843726 DOI: 10.1001/Archotol.128.2.167 |
0.692 |
|
| 2001 |
Ji C, Amarnath V, Pietenpol JA, Marnett LJ. 4-Hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release Chemical Research in Toxicology. 14: 1090-1096. PMID 11511183 DOI: 10.1021/Tx000186F |
0.334 |
|
| 2001 |
Szak ST, Mays D, Pietenpol JA. Kinetics of p53 binding to promoter sites in vivo. Molecular and Cellular Biology. 21: 3375-86. PMID 11313463 DOI: 10.1128/Mcb.21.10.3375-3386.2001 |
0.826 |
|
| 2001 |
Stewart ZA, Pietenpol JA. p53 Signaling and cell cycle checkpoints. Chemical Research in Toxicology. 14: 243-63. PMID 11258974 DOI: 10.1021/Tx000199T |
0.734 |
|
| 2001 |
Stewart ZA, Pietenpol JA. Syk: a new player in the field of breast cancer. Breast Cancer Research : Bcr. 3: 5-7. PMID 11250739 DOI: 10.1186/Bcr261 |
0.677 |
|
| 2001 |
Stewart ZA, Tang LJ, Pietenpol JA. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene. 20: 113-24. PMID 11244509 DOI: 10.1038/Sj.Onc.1204060 |
0.756 |
|
| 2000 |
Flatt PM, Pietenpol JA. Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Drug Metabolism Reviews. 32: 283-305. PMID 11139130 DOI: 10.1081/Dmr-100102335 |
0.781 |
|
| 2000 |
Song SY, Meszoely IM, Coffey RJ, Pietenpol JA, Leach SD. K-Ras-independent effects of the farnesyl transferase inhibitor L- 744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells Neoplasia. 2: 261-272. PMID 10935512 DOI: 10.1038/Sj.Neo.7900088 |
0.362 |
|
| 2000 |
Flatt PM, Polyak K, Tang LJ, Scatena CD, Westfall MD, Rubinstein LA, Yu J, Kinzler KW, Vogelstein B, Hill DE, Pietenpol JA. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Letters. 156: 63-72. PMID 10840161 DOI: 10.1016/S0304-3835(00)00441-9 |
0.835 |
|
| 2000 |
Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Molecular and Cellular Biology. 20: 4210-23. PMID 10825186 DOI: 10.1128/Mcb.20.12.4210-4223.2000 |
0.822 |
|
| 1999 |
Stewart ZA, Pietenpol JA. Cell cycle checkpoints as therapeutic targets. Journal of Mammary Gland Biology and Neoplasia. 4: 389-400. PMID 10705922 DOI: 10.1023/A:1018770417964 |
0.702 |
|
| 1999 |
Stewart ZA, Mays D, Pietenpol JA. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Research. 59: 3831-7. PMID 10447002 |
0.729 |
|
| 1999 |
Szak ST, Pietenpol JA. High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain. The Journal of Biological Chemistry. 274: 3904-9. PMID 9920946 DOI: 10.1074/Jbc.274.6.3904 |
0.782 |
|
| 1999 |
Stewart ZA, Leach SD, Pietenpol JA. p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Molecular and Cellular Biology. 19: 205-15. PMID 9858545 DOI: 10.1128/Mcb.19.1.205 |
0.764 |
|
| 1998 |
Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, Pietenpol JA. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. The Journal of Biological Chemistry. 273: 30777-84. PMID 9804855 DOI: 10.1074/Jbc.273.46.30777 |
0.676 |
|
| 1998 |
Leach SD, Scatena CD, Keefer CJ, Goodman HA, Song SY, Yang L, Pietenpol JA. Negative regulation of wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis Cancer Research. 58: 3231-3236. PMID 9699647 |
0.422 |
|
| 1998 |
Flatt PM, Price JO, Shaw A, Pietenpol JA. Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 9: 535-43. PMID 9690621 |
0.757 |
|
| 1998 |
Ji C, Rouzer CA, Marnett LJ, Pietenpol JA. Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde Carcinogenesis. 19: 1275-1283. PMID 9683189 DOI: 10.1093/Carcin/19.7.1275 |
0.497 |
|
| 1998 |
Jennings MT, Pietenpol JA. The role of transforming growth factor β in glioma progression Journal of Neuro-Oncology. 36: 123-140. PMID 9525812 DOI: 10.1023/A:1005863419880 |
0.349 |
|
| 1997 |
Ji C, Marnett LJ, Pietenpol JA. Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels Oncogene. 15: 2749-2753. PMID 9401002 DOI: 10.1038/Sj.Onc.1201441 |
0.527 |
|
| 1997 |
Coursen JD, Bennett WP, Khan MA, Forrester K, Pietenpol JA, Harris CC. Differential effects of p53 mutants on the growth of human bronchial epithelial cells. Molecular Carcinogenesis. 19: 191-203. PMID 9254886 DOI: 10.1002/(Sici)1098-2744(199707)19:3<191::Aid-Mc7>3.0.Co;2-H |
0.404 |
|
| 1997 |
Koury MJ, Horne DW, Brown ZA, Pietenpol JA, Blount BC, Ames BN, Hard R, Koury ST. Apoptosis of late-stage erythroblasts in megaloblastic anemia: Association with DNA damage and macrocyte production Blood. 89: 4617-4623. PMID 9192787 DOI: 10.1182/Blood.V89.12.4617 |
0.315 |
|
| 1997 |
Ji C, Pietenpol JA, Marnett LJ. Bc12 prevents human cancer cells from 4hydroxynonenal induced apoptosis Faseb Journal. 11. |
0.354 |
|
| 1996 |
Pietenpol JA, Lengauer C, Jordan J, Kinzler KW, Vogelstein B. Mammalian cells resistant to tumor suppressor genes Proceedings of the National Academy of Sciences of the United States of America. 93: 8390-8394. PMID 8710881 DOI: 10.1073/Pnas.93.16.8390 |
0.499 |
|
| 1995 |
Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Research. 55: 1206-10. PMID 7882309 |
0.425 |
|
| 1994 |
Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry WS, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53 Proceedings of the National Academy of Sciences of the United States of America. 91: 1998-2002. PMID 8134338 DOI: 10.1073/Pnas.91.6.1998 |
0.5 |
|
| 1994 |
El-Deiry WS, O'Connor PM, Burrell M, Wang Y, Elledge SJ, Harper JW, Mercer WE, Velculescu VE, Jackman J, Hill DE, Wiman KG, Canman CE, Kohn KW, Pietenpol JA, Kastan MB, et al. WAF1/CIP1 Is Induced in p53-mediated G1 Arrest and Apoptosis Cancer Research. 54: 1169-1174. PMID 8118801 |
0.467 |
|
| 1994 |
Pietenpol JA, Markowitz S, Papadopoulos N, Willson JKV, Kinzler KW, Vogelstein B. Paradoxical Inhibition of Solid Tumor Cell Growth by bcl2 Cancer Research. 54: 3714-3717. PMID 8033089 |
0.303 |
|
| 1993 |
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 Nature. 362: 857-860. PMID 8479525 DOI: 10.1038/362857A0 |
0.492 |
|
| 1993 |
Pietenpol JA, Vogelstein B. No room at the p53 inn Nature. 365: 17-18. PMID 8361531 DOI: 10.1038/365017A0 |
0.47 |
|
| 1992 |
Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression Science. 256: 827-830. PMID 1589764 DOI: 10.1126/Science.1589764 |
0.541 |
|
| 1992 |
El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53 Nature Genetics. 1: 45-49. PMID 1301998 DOI: 10.1038/Ng0492-45 |
0.444 |
|
| 1991 |
Pietenpol JA, Münger K, Howley PM, Stein RW, Moses HL. Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. Proceedings of the National Academy of Sciences of the United States of America. 88: 10227-31. PMID 1946442 DOI: 10.1073/Pnas.88.22.10227 |
0.314 |
|
| 1991 |
Murphy CS, Pietenpol JA, Munger K, Howley PM, Moses HL. c-myc and pRB: Role in TGF-β1 inhibition of keratinocyte proliferation Cold Spring Harbor Symposia On Quantitative Biology. 56: 129-135. PMID 1819482 DOI: 10.1101/Sqb.1991.056.01.017 |
0.322 |
|
| 1990 |
Pietenpol JA, Holt JT, Stein RW, Moses HL. Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proceedings of the National Academy of Sciences of the United States of America. 87: 3758-62. PMID 2187192 DOI: 10.1073/Pnas.87.10.3758 |
0.304 |
|
| 1990 |
Pietenpol JA, Stein RW, Moran E, Yaciuk P, Schlegel R, Lyons RM, Pittelkow MR, Münger K, Howley PM, Moses HL. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell. 61: 777-85. PMID 2140528 DOI: 10.1016/0092-8674(90)90188-K |
0.313 |
|
| 1989 |
Pietenpol JA, Howe PH, Cunningham MR, Leof EB. Interferon α/β modulation of growth-factor-stimulated mitogenicity in AKR-2B fibroblasts Journal of Cellular Physiology. 141: 453-460. PMID 2687295 DOI: 10.1002/Jcp.1041410302 |
0.306 |
|
| Show low-probability matches. |